Himalaya Wellness Company Extends Support to Sankalp India Foundation to Support Thalassemia Patients
Bengaluru, April 08th, 2022: To make Thalassemia treatment accessible to underprivileged children, Himalaya Wellness Company, one of India’s leading wellness brands, has partnered with Sankalp India Foundation (SIF). As a part of Himalaya’s support to SIF, children suffering from Thalassemia will be identified through Sankalp’s Program for Thalassemia Cure and offered the permanent curative option, a bone marrow transplant, giving them a new lease on life.
Every year, over 10,000 children are born with Thalassemia. Thalassemia is an inherited blood disorder, and a bone marrow transplant is the only permanent cure. The cost of the treatment is extremely high in India, ranging up to INR 15,00,000, making it inaccessible for the poor.
Speaking on the initiative, K G Umesh, Director Human Resources, Himalaya Wellness Company, shares, “Care for Life, a part of our business philosophy, sits at the heart of Himalaya Wellness Company. Our business philosophy defines the way we think and inspires our actions. Through our commitment to address community health care challenges, we are happy to extend our support to SIF to make systematic care and management of thalassemia accessible. Through this partnership, we will make a positive difference in the lives of children and exemplify our vision to provide happiness by empowering and enabling communities to lead happier lives.”
Lalith Parmar, President, SIF, shares, “We are extremely grateful to Himalaya for this gesture. Sankalp’s Program for Thalassemia Cure identifies children who are suffering from thalassemia and offers them the permanent curative option. At the cost equivalent to 4-5 years of thalassemia management, we have offered a complete cure from the disease to over 400 children in the past five years. Further, our partnership with Himalaya will be a step forward in ensuring more patients get access to the treatment and helping realize our goal of a thalassemia-free India.”
Patients will undergo treatment at the at BMJH-Sankalp Department of Pediatric haematology-oncology and BMT, Bhagwan Mahaveer Jain Hospital, Bengaluru, which was inaugurated in September 2021.
